Revenue (Tables)

6 Months Ended

Jun. 30, 2023

Risks and Uncertainties [Abstract]

Schedule of disaggregation of revenue

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:

	Three Months Ended June 30,				Six Months Ended June 30,
Revenue by product (in thousands)	2023		2022		2023		2022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)	$	22,377	$	15,714	$	45,331	$	31,009
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	4,015		4,295		8,004		7,803
Implants sold direct based on contracted rates (c)	7,252		5,756		14,222		11,390
Implants sold direct subject to third-party reimbursement (d)	1,045		570		1,538		1,441
Biopsy kits - direct bill	528		545		1,062		1,066
Change in estimates related to prior periods (e)	1,119		1,733		369		1,898
Total MACI implants and kits	36,336		28,613		70,526		54,607
Epicel
Direct bill (hospital)	9,586		8,213		16,413		18,071
NexoBrid revenue (f)	—		220		—		442
Total revenue	$	45,922	$	37,046	$	86,939	$	73,120
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).